A Phase 1b, Prospective, Randomized, Double-Blind, Placebo- Controlled, Single-Dose, Multicenter, Safety Study of FX-322 Administered by Intratympanic Injection in Adults With Severe Sensorineural Hearing Loss
Latest Information Update: 03 Feb 2022
At a glance
- Drugs FX 322 (Primary)
- Indications Sensorineural hearing loss
- Focus Adverse reactions; Therapeutic Use
- Sponsors Frequency Therapeutics
- 31 Jan 2022 Status changed from active, no longer recruiting to completed.
- 09 Dec 2021 Results published in the Frequency Therapeutics Media Release.
- 12 Aug 2021 According to a Frequency Therapeutics media release, company expects to share topline results from this study in Q4 2021.